MedTrace Logo

Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cancer (KATIA)

NCT03829306 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2023-01-13

No results posted yet for this study

Summary

The study aim is to perform a comprehensive and integrated characterization of mechanisms of primary and acquired resistance to Kadcyla in a prospective cohort of progressive/recurrent HER2-positive breast cancer patients.

Conditions

Sponsors & Collaborators

  • Roche Farma, S.A

    collaborator INDUSTRY

  • Spanish Breast Cancer Research Group

    lead OTHER

Principal Investigators

  • Study director · Hospital del Mar, Barcelona, Spain

  • Study director · Fundación Jiménez-Díaz, Madrid, Spain

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-12
Primary Completion
2022-06-21
Completion
2022-06-21

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03829306 on ClinicalTrials.gov